The global Preclinical Imaging Market size was estimated at USD USD 870.4 Mn in 2021, growing at a CAGR of 7.1% during the forecast period 2021-2027. Preclinical imaging is used during drug discovery process in live animals. Preclinical imaging used for monitoring the treatment regime responses helpful for obtaining the early indications of efficacy. Technological improvements and advances in in-vivo clinical study providing the new opportunities to understand the clearly molecular level of details. Major preclinical imaging is targeted for diseases such as autoimmune diseases, cancers, cardiovascular diseases, and neurological disorders and others. Surge in adoption of sophisticated diagnostic technologies coupled with increased early diagnosis have expected to accelerate global preclinical imaging market. According to American Cancer Society, 14.1 million new cancer cases were diagnosed and 8.2 million cancer deaths in 2012. Companies adopting product innovations to increase their market share. Currently, the most used imaging modalities are optical (fluorescence and bioluminescence), PET, and MRI. In addition, multi-modalities such as PET+CT and SPECT+CT are the most used imaging combinations. In-vivo imaging is increased usage in target identification, compound optimization and pre-Phase I study, and in the drug development process. Thus, it bridges the gap between in-vitro exploratory and in-vivo clinical research. Regions such as Latin America, Middle East, and Asia Pacific are witnessing an increase in foreign investments that is leading to greater revenue generation, for the market growth.